Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Familial amyloid polyneuropathy

M M Reilly1, R H King

  • 1University Department of Clinical Neurology, Institute of Neurology, London, U.K.

Brain Pathology (Zurich, Switzerland)
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported disease burden in the Accelerate Clinical Trials in Charcot-Marie-Tooth Disease Study.

Journal of the peripheral nervous system : JPNS·2024
Same author

The integrated stress response contributes to tRNA synthetase-associated peripheral neuropathy.

Science (New York, N.Y.)·2021
Same author

Are we prepared for clinical trials in Charcot-Marie-Tooth disease?

Brain research·2020
Same author

Routine blood monitoring in maintenance immunoglobulin treatment of inflammatory neuropathy: Is it clinically relevant?

Journal of the neurological sciences·2019
Same author

Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X.

Human molecular genetics·2019
Same author

Spinal Stenosis in Familial Transthyretin Amyloidosis.

Journal of neuromuscular diseases·2019
Same journal

Distinctly altered TRPC3 and TRPC6 expression patterns in human Alzheimer's disease cortex and hippocampus.

Brain pathology (Zurich, Switzerland)·2026
Same journal

Lewy bodies are surrounded by granulovacuolar degeneration bodies in dementia with Lewy bodies.

Brain pathology (Zurich, Switzerland)·2026
Same journal

Chromosomal and immune dysregulation underlying granular mitosis in glioblastoma.

Brain pathology (Zurich, Switzerland)·2026
Same journal

Nearest-neighbors assisted unsupervised analysis for methylation array profiling for central nervous system tumors.

Brain pathology (Zurich, Switzerland)·2026
Same journal

AOSNP-ADAPTR resource level-based recommendations on practical diagnostic strategies for ependymomas.

Brain pathology (Zurich, Switzerland)·2026
Same journal

Comments to the "Letter to the Editor" for the manuscript titled "Increased expression of inflammasome signaling genes and proteins in selective brain regions in the intermediate stage of Alzheimer's disease".

Brain pathology (Zurich, Switzerland)·2026
See all related articles

Familial amyloid polyneuropathy (FAP) is linked to genetic defects in transthyretin and other proteins. Classifying FAP by its genetic cause is now preferred, and liver transplantation shows promise for treatment.

Area of Science:

  • Genetics and Molecular Biology
  • Neurology
  • Medical Research

Background:

  • Familial amyloid polyneuropathy (FAP) is primarily associated with variant plasma transthyretin, but also with mutant apolipoprotein A-1 and gelsolin.
  • Over 26 point mutations in the transthyretin gene are now identified as causes of FAP.
  • Clinical presentations of FAP can overlap significantly between different mutations.

Purpose of the Study:

  • To highlight the importance of classifying FAP based on underlying genetic defects rather than clinical phenotypes.
  • To address unanswered questions regarding the amyloidogenic properties of transthyretin and mutation-specific organ involvement.
  • To evaluate the potential of liver transplantation as a therapeutic strategy for FAP.

Main Methods:

  • Review of existing literature on FAP genetics, clinical manifestations, and treatment modalities.

Related Experiment Videos

  • Analysis of the correlation between specific transthyretin gene mutations and FAP phenotypes.
  • Assessment of the efficacy and implications of liver transplantation in FAP patients.

    • Main Results:

    • A shift in classification from clinical grounds to genetic defects is recommended for FAP.
    • Significant variability in organ involvement exists, influenced by the specific underlying genetic mutation.
    • Liver transplantation has emerged as a promising treatment option for FAP.

    Conclusions:

    • Genetic classification provides a more accurate framework for understanding and managing FAP.
    • Further research is needed to fully elucidate the mechanisms of transthyretin amyloidogenesis and organ specificity.
    • Liver transplantation offers a potentially effective therapeutic avenue for patients with FAP.